Publications

Read Now

November 2007
Case

Antegren: A Beacon of Hope

By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann

The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details

Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Pharmaceutical Industry; Pharmaceutical Industry

December 2005 (Revised October 2006)
Case

Pharmacy Service Improvement at CVS (A)

CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems... View Details

Keywords: Information Technology; Performance Improvement; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry; United States

January 2005 (Revised March 2006)
Case

Molecular Insight Pharmaceuticals, Inc.

By: Richard G. Hamermesh and Edwin W. Parkinson III

Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing.... View Details

Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry

April 1993 (Revised May 1994)
Case

Genzyme Corporation: Strategic Challenges with Ceredase

Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details

Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States

May 1992
Teaching Note

RU 486 (A) and (B), Teaching Note

By: Joseph L. Badaracco Jr.

Teaching Note for (9-391-050) and (9-391-051). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States

October 1990 (Revised April 1991)
Case

RU 486 (A)

By: Joseph L. Badaracco Jr.

Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details

Keywords: Judgments; Ethics; Product Launch; Negotiation; Outcome or Result; Performance; Business and Government Relations; Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States

09 Feb 2016
First Look

February 9, 2016

challenges as it seeks to continue its growth. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/816013-PDF-ENG Harvard Business School Case 316-010 The Allergan Board Under Fire (A) In 2014, the Allergan Inc. board of directors received a surprise takeover... View Details

Keywords: Sean Silverthorne

26 Sep 2006
First Look

First Look: September 26, 2006

patient needs and working backwards to develop profitable solutions rather than starting with the government, pharmaceutical or healthcare industry or NGO. The examination is undertaken on two levels, a macro level that focuses on... View Details

Keywords: Sean Silverthorne

19 Sep 2012
Research & Ideas

Funding Innovation: Is Your Firm Doing it Wrong?

the scale and resources of the corporate lab with some of the intensity and urgency associated with the venture capital model, you have something that can be very, very strong," Lerner says. The book describes how, in 2008, the View Details

Keywords: by Carmen Nobel

July 2017 (Revised July 2019)
Supplement

"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B)

By: Nori Gerardo Lietz and Ricardo Andrade

The B Case of "Dr. My Eyes" provides the answer as to what happened after the ending fact pattern in Case A and the imminent choices faced by the protagonist in the primary case. At the end of the Case A, Bess Weatherman of Warburg Pincus, must chose one option of two... View Details

Keywords: Private Equity; Health Care and Treatment; Mergers and Acquisitions; Corporate Governance; Decision Choices and Conditions; Outcome or Result; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry

July 2016 (Revised July 2019)
Teaching Plan

Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)

By: Nori Gerardo Lietz and Ricardo Andrade

In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details

Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States

April 2016 (Revised July 2019)
Case

"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)

By: Nori Gerardo Lietz

In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details

Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States

August 2003
Teaching Note

Pharmacyclics: Financing Research and Development (TN)

By: Malcolm P. Baker and Richard S. Ruback

Teaching Note for (9-201-056). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry

03 Aug 2016
What Do You Think?

How Can We Hold the “Leadership Industry” Accountable?

these leadership industry issues varied. Pradip commented: “In a competitive industry there are many who want everyone to ‘buy in’ (to) their half baked research as ‘new truth.’” He called for a “rigorous research methodology” like what is used to test View Details

Keywords: by James Heskett; Education

21 Apr 2014
Research & Ideas

Bio-Piracy: When Western Firms Usurp Eastern Medicine

communities that traditionally use the herb. The paper cites two key examples of local communities benefiting from a firm's herbal patent. In one case, members of Indian Kani tribe received royalties for the pharmaceutical version of the... View Details

Keywords: by Carmen Nobel; Legal Services; Biotechnology

10 Jun 2008
First Look

First Look: June 10, 2008

Formula’ Harvard Business School Case 808-127 Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with... View Details

Keywords: Martha Lagace

05 Jul 2004
Research & Ideas

Radical Change, Entrepreneurial Opportunity

tightly coupled relationships with customers to engage in trials of different product concepts, producers and users can jointly learn about and make sense of the new technology. For instance, Surface Logix, a firm with highly sophisticated, flexible technology called... View Details

Keywords: by Michael J. Roberts; Technology

12 Mar 2014
Research & Ideas

Entrepreneurship and Multinationals Drive Globalization

In a new book on the origins and impacts of globalization, Harvard Business School's Geoffrey Jones focuses on the role played by a vital but often ignored actor in this conversation: business entrepreneurs and the multinational enterprises they create. "There has... View Details

Keywords: by Sean Silverthorne; Pharmaceutical; Pharmaceutical; Pharmaceutical; Pharmaceutical

February 2018 (Revised April 2018)
Case

Yunnan Baiyao: Transforming a Chinese State-Owned Enterprise

By: Michael Chu, William C. Kirby, Nancy Hua Dai and Yuanzhuo Wang

This case tells the story of how Wang Minghui, Chairman of Yunnan Baiyao Group since 1999, transformed a single-product traditional Chinese medicine (TCM) state-owned enterprise (SOE) into a major diversified consumer health player in China's highly competitive... View Details

Keywords: State-owned Enterprise (SOE); Traditional Chinese Medicine; Yunnan; Yunnan Baiyao; Consumer Health; Enterprise Transformation; Transformation; Health; Business History; State Ownership; Private Ownership; Business Strategy; Commercialization; Competition; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; China